Deutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating

FierceBiotechRegeneron pays $37M, adds $2B in biobucks to expand CytomX pact

PharmaVoiceWhen the ISS comes down, will its drug R&D be lost in space?

FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of age

FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system

10x Genomics NewsDeutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com

FierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases

Endpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

BioPharma DiveLilly, Ascidian link up in RNA exon editing pact

CellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorins

CellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defense

LabiotechSurge in M&As driven by patent expirations

Thermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum Asia